Loading...

PPLPHARMA Piramal Pharma Ltd Other Situations Announcement

Prml

PPLP

Piramal Pharma Ltd

(PPLPHARMA)

2025 Announcement

Show Summary

Summary

Investor Meet Summary

Conference Call Audio

Q1 FY26 Results

Stock Options Granted

Unit Sale Approved

Credit Rating Upgrade

Investor Call Announcement

ESG Rating Update

Litigation Update

AGM Notice Published

AGM Announcement

Auditor Appointments

Auditor Appointments

Investor Meeting Schedule

FDA Inspection Success

Secretarial Compliance Report

Conference Call Summary

Investor Call Recording

Directorate Changes

Financial Results

Q4 FY2025 Results

Capacity Expansion

FDA Inspection Closed

Investor Meetings

Investor Conference Call

Acquisition Announcement

Sevoflurane Production Start

Analyst Meetings

Postal Ballot Notice

FDA Inspection Results

Domain Name Change

Investor Meetings

Sale Timeline Extended

Earnings Call Transcript

Financial Results Call

Conference Call Recording

Corporate Guarantee Issued

Investor Presentation

Financial Results Q3

Director Appointment

GST Penalty Received

Corporate Guarantee Issued

Investor Meeting Schedule

Investor Call Announced

Management Change

Registrar Name Change

RTA Name Change

Litigation Settlement

Corporate Guarantee Issued

Investor Meetings

Earnings Call Summary

Audio Conference Call

Financial Results Update

Q2 FY25 Results

Credit Rating Update

Regulatory Compliance

Investor Call Scheduled

Penalty Notification

Management Change

Sustainability Report Released

Sustainability Report 2023-24

Sustainability Report Released

Facility Expansion Plan

Facility Expansion

FDA Inspection Report

Investor Presentation

Investor Meeting

Sustainability Commitment

Share Subscription Deal

Investor Meetings

Analyst/Investor Meetings

Credit Rating Update

Earnings Call Outcome

Financial Results Announcement

Financial Results

Stock Options Grant

Stock Options Grant

Acquisition Approval

Conference Call Intimation

FDA Inspection Closure

Penalty Disclosure

AGM and Dividend Record Dat...

Litigation Update

Secretarial Compliance Report

FDA Inspection Closure

Analyst Meetings

Conference Call Recording

Director Resignation

Report Submission

Financial Results Announcement

Financial Results Announcement

Product Campaign Launch

Conference Call Intimation

Assessment Orders

Financial Default

Compliance Certificate

Compliance Certificate Subm...

FDA Inspection Closure

Website Domain Change

FDA Inspection Observations

Meeting Schedule

US FDA Inspection

Conference Call Recording

Monitoring Agency Report

Financial Results Announced

Financial Results Announcement

Conference Call with Invest...

Analyst Meetings

Litigation Details

Analyst/Investor Meet

Schedule of Analyst / Inves...

Analyst/ Investor Meet

Litigation Filed

Successful Closure of US FD...

Investor Meetings

Transcript Release

Analyst/ Investor Meet

Conference Call Audio Recor...

Monitoring Agency Report

Financial Results Approval

Financial Results

Financial Results Announcement

Certificate of Reconciliation

Conference Call

Investment Announcement

FDA Inspection Closure

Rights Issue Allotment

Liquidation Approval

Sustainability Report

Equity Offerings

Meetings Schedule

Financial Statements

Rights Offerings

Financial Statements

Financial Statements

Financial Statements

Board Composition

Stock-Based Compensation

Conference Call

Conference Call

Rights Offerings

Rights Offerings

Rights Offerings

Investor Meetings

AGM Announcement

Financial Results Transcript

Conference Call

Financial Results Announcement

Financial Results

Conference Call

External Links:

Data:

Piramal Pharma Ltd has received an ESG rating of 61 for FY 2023-24 from NSE Sustainability, disclosed on July 10, 2025, based on voluntary assessment of public data. The company did not engage NSE Sustainability for this rating.

AI Assistant

Piramal Pharma Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.